While gap junctions support the exchange of a number of molecules between neighboring cells, connexin hemichannels provide communication between the cytosol and the extracellular environment of an individual cell. The latter equally holds true for channels composed of pannexin proteins, which display an architecture reminiscent of connexin hemichannels. In physiological conditions, gap junctions are usually open, while connexin hemichannels and, to a lesser extent, pannexin channels are typically closed, yet they can be activated by a number of pathological triggers. Several agents are available to inhibit channels built up by connexin and pannexin proteins, including alcoholic substances, glycyrrhetinic acid, anesthetics and fatty acids. These compounds not always strictly distinguish between gap junctions, connexin hemichannels and pannexin channels, and may have effects on other targets as well. An exception lies with mimetic peptides, which reproduce specific amino acid sequences in connexin or pannexin primary protein structure. In this paper, a state-of-the-art overview is provided on inhibitors of cellular channels consisting of connexins and pannexins with specific focus on their mode-of-action and therapeutic potential.
Introduction
Direct intercellular communication is mediated by gap junctions (GJs), which can exchange a number of small molecules, such as adenosine triphosphate (ATP), glutamate and prostaglandins, as well as ions, including Ca 2+ , between the cytosolic compartments of adjacent cells (Hertzberg, Lawrence, & Gilula, 1981) . This flux is called gap junctional intercellular communication (GJIC) . GJs arise from the interaction between 2 hemichannels (HCs) of neighboring cells, which in turn are composed of 6 connexin (Cx) proteins (Maes et al., 2014) . In recent years, it has become clear that Cx HCs are not merely structural precursors of GJs, as they also can provide a circuit for communication, albeit between the cytosol and the extracellular environment (Kar, Batra, Riquelme, & Jiang, 2012; Vinken et al., 2011) . Today, 21 different Cx types have been identified in a myriad of human and mouse cell types (Table 1) , all which share a similar structure consisting of 4 transmembrane domains, 2 extracellular loops (EL), 1 cytoplasmic loop (CL), 1 cytoplasmic C-terminal tail (CT) and 1 cytoplasmic N-terminal tail ( Fig. 1 ) (Vinken et al., 2008; Willebrords et al., 2015) . Since various tissues express more than 1 Cx type, homotypic, heterotypic, homomeric and heteromeric GJs may form between cells. GJs can be regulated by different mechanisms, including pH, transmembrane voltage and Ca 2+ Table 1 Connexin and pannexin expression in different cell types. (Cx, connexin; Panx, pannexin).
Organ
Cell type Cx/Panx species References Brain Astrocytes Cx30, Cx43, Panx1, Panx2 (Boassa, Nguyen, Hu, Ellisman, & Sosinsky, 2014; Dermietzel, Hertberg, Kessler, & Spray, 1991; Nagy & Rash, 2000) 
Microglial cells
Cx26, Cx32, Panx1 (Eugenín et al., 2001; Garg, Md Syed, & Kielian, 2005; Kielian, 2008; Parenti, Campisi, Vanella, & Cicirata, 2002; Penuela, Gehi, & Laird, 2013; Takeuchi et al., 2006 ) Oligodendrocytes Cx32, Cx47, Cx29 (Altevogt, Kleopa, Postma, Scherer, & Paul, 2002; Dermietzel et al., 1989; Odermatt et al., 2003) Neurons Cx36, Cx45, Panx1, Panx2 (Boassa et al., 2014; Penuela et al., 2013; Takeuchi & Suzumura, 2014 ) Blood-brain barrier endothelial cells Cx37, Cx40, Cx43 (De Bock et al., 2014; Little, Beyer, & Duling, 1995; Nagasawa et al., 2006; Traub et al., 1998 ) Blood-brain barrier pericytes Cx37, Cx40, Cx43 (De Bock et al., 2014; Little et al., 1995; Nagasawa et al., 2006; Traub et al., 1998) Heart Smooth muscle cells Cx40, Cx43, Cx45 (Gros & Jongsma, 1996; Severs et al., 2004 ) Cardiomyocytes Cx40, Cx43, Cx45, Panx1 (Gros & Jongsma, 1996; Petric et al., 2016; Severs et al., 2004 ) Blood vessels Endothelial cells Cx43, Cx37, Cx40, Panx1 (Chadjichristos et al., 2010; Lohman et al., 2012; Lohman et al., 2015; Scheckenbach et al., 2011 ) Smooth muscle cells Cx43, Cx45, Cx40, Cx37, Panx1 (Chadjichristos et al., 2010; Scheckenbach et al., 2011) Liver Sinusoidal endothelial cells Cx26, Cx43 (Hernández-Guerra et al., 2014) Hepatic arteries and portal vein endothelial cells Cx37, Cx40 (Fischer et al., 2005; Shiojiri, Niwa, Sugiyama, & Koike, 2006) Hepatocytes Cx26, Cx32, Panx1, Panx2 (Crespo Yanguas et al., 2017; Iwata, Joh, Ueda, Yokoyama, & Itoh, 1998; Kyoi, Ueda, Kimura, Yamamoto, & Kataoka, 1992; Maes et al., 2015; Ohkusa, Fujiki, Tamura, Yamamoto, & Kyoi, 1995; Radebold et al., 2001 ) Kupffer cells Cx26, Cx43, Panx1 (Crespo Yanguas et al., 2017; Eugenín, González, Sánchez, Brañes, & Sáez, 2007; González et al., 2002 ) Stellate cells Cx26, Cx43 (Fischer et al., 2005; Maes et al., 2015) Stomach and intestines Stomach Cx26, Cx32, Cx40, Cx43, Cx45 (Cousins, Edwards, Hickey, Hill, & Hirst, 2003; Liu et al., 2010; Wang & Daniel, 2001; Wang et al., 2014 ) Foveolar cells Cx32 (Fink et al., 2006 ) Small intestine Cx26, Cx31, Cx57 (Filippov, Hormuzdi, Fuchs, & Monyer, 2003 ) Myenteric plexus cells Cx36, Cx40, Cx43, Cx45 (Frinchi et al., 2013; Liu, Zhang, He, & Song, 2008; Wang & Daniel, 2001 ) Small intestine epithelial cells Cx32, Cx37, Cx43 (Hakim, Jackson, & Segal, 2008; Husøy et al., 2004; Traoré et al., 2003) Interstitial cells of cajal Cx43 (Seki & Komuro, 2002 ) Colon Cx31, Cx31.9, Cx43 (Ismail et al., 2014; Li, Zhang, et al., 2015 , Li, Zhou, et al., 2015 Musculus externa cells Cx26, Cx40, Cx43, Panx1 Mattii et al., 2013; Wang & Daniel, 2001 ) Myenteric plexus cells Cx36, Cx40, Cx43, Cx45 (Frinchi et al., 2013; McClain et al., 2014; Wang & Daniel, 2001 ) Epithelial cells Cx26, Cx32, Cx37, Cx43, Panx2 (Kanady, Munger, Witte, & Simon, 2015; Kanczuga-Koda, Sulkowski, Koda, Sobaniec-Lotowska, & Sulkowska, 2004; Maes et al., 2015) Muscularis mucosa cells Cx43, Panx1 (Ismail et al., 2014; Maes et al., 2015 ) Skin Keratinocytes Cx26, Cx30.3, Cx30, Cx31.1, Cx31, Cx40, Cx43, Cx45, Panx1, Panx3 (Brandner, Houdek, Hüsing, Kaiser, & Moll, 2004 Churko & Laird, 2013; Cowan, Langlois, Penuela, Cowan, & Laird, 2012; Di et al., 2001; Martin et al., 2014; Wang, Lincoln, et al., 2007; Wang, Ma, et al., 2007) Fibroblasts Cx43, Cx45, Cx40 (Cogliati et al., 2015; Meyer et al., 2014; Tarzemany, Jiang, Larjava, & Häkkinen, 2015; Wright et al., 2009 ) Melanocytes Cx43 (Haass, Smalley, & Herlyn, 2004; Penuela et al., 2012; Rezze, Fregnani, Duprat, & Landman, 2011) Kidney Smooth muscle cells Cx37, Cx45 (Arensbak, Mikkelsen, Gustafsson, Christensen, & Holstein-Rathlou, 2001; Hanner, Sorensen, Holstein-Rathlou, & Peti-Peterdi, 2010; Li, Zhang, et al., 2015 , Li, Zhou, et al., 2015 ) Podocytes Cx43, Cx45 (Hanner et al., 2010; Morioka et al., 2013; Yang, Wang, Li, & Jiang, 2014 ) Pericytes Cx37 (Hanner et al., 2010; 
Mesangial cells
Cx40, Cx45 (Arensbak et al., 2001; Hanner et al., 2010; Kurtz et al., 2007; Morioka et al., 2013 ) Lung Alveolar epithelium Cx26, Cx32, Cx43, Cx46, Panx1, Panx2 (Koval, 2002; Lohman et al., 2012; Lohman et al., 2015) Eye Lens epithelial cells Cx43, Cx46, Cx50, Panx1 (Berthoud, Minogue, Osmolak, Snabb, & Beyer, 2014; Slavi et al., 2014 (Alves et al., 1996; Beyer & Steinberg, 1991; Kwak et al., 2002 ) Neutrophils Cx43, Panx1 (Glass et al., 2015) Dendritic cells Cx43, Panx1 (Glass et al., 2015 ) Pancreas β-Cells Cx36, Cx43, Cx45 (Charollais et al., 1999 ) Exocrine pancreas Cx32, Panx1 (Frossard et al., 2003; Kowal, Yegutkin, & Novak, 2015) Skeletal muscle Myoblasts Cx39, Cx40, Cx43, Cx45, Panx1, Panx3 (Langlois & Cowan, 2016; Merrifield & Laird, 2015) Bone Osteocytes Cx37, Cx43 (Krüger et al., 2000; Pacheco-Costa et al., 2014; Paic et al., 2009 ) Osteoblasts Cx37, Cx43, Cx45, Cx46, Panx3 (Chaible, Sanches, Cogliati, Mennecier, & Dagli, 2011 Civitelli et al., 1993; Donahue et al., 1995; Krüger et al., 2000; Penuela et al., 2013; Plotkin & Bellido, 2013 ) Osteoclasts Cx37, Cx43 (Pacheco-Costa et al., 2014 Paic et al., 2009 ) Chondrocytes Cx32, Cx43, Cx45, Cx46, Panx3 (Mayan et al., 2013; Penuela et al., 2013) concentration (Cottrell & Burt, 2005) . Posttranslational modifications, such as S-nitrosylation, ubiquitination, sumoylation and phosphorylation, also directly regulate GJ opening (Johnstone, Billaud, Lohman, Taddeo, & Isakson, 2012 Vuyst et al., 2006; Wang et al., 2013a Wang et al., , 2013b or decreases in extracellular Ca 2+ concentration (Srinivas, Calderon, Kronengold, & Verselis, 2006) , mechanical stimulation (Luckprom, Kanjanamekanant, & Pavasant, 2011) , changes in the Cx phosphorylation status (Alstrom, Stroemlund, Nielsen, & MacAulay, 2015) , oxidative stress , ischemia/reperfusion insults (Wang et al., 2013a (Wang et al., , 2013b , fatty acid overload (Puebla, Retamal, Acuña, & Sáez, 2017) and inflammatory conditions (Willebrords et al., 2016) . In this respect, it has been shown that Cx channels are important players in pathological conditions, such as inflammation (Willebrords et al., 2016) , gastrointestinal and liver disease (Maes, Crespo Yanguas, Willebrords, Cogliati, & Vinken, 2015) , wound healing (Wright, van Steensel, Hodgins, & Martin, 2009 ), brain and spinal cord injury (Tonkin et al., 2014) , ischemia/reperfusion injury (Wang et al., 2013a (Wang et al., , 2013b , atherosclerosis (Morel, Burnier, & Kwak, 2009) and lung disease (Sarieddine et al., 2009) . In 2000, a novel class of Cx-like proteins, the pannexin (Panx) proteins, has been identified. They assemble in Cx HC-like configuration and do not form GJs ( Fig. 1) (Wang et al., 2013a (Wang et al., , 2013b . The Panx family consists of 3 members, namely Panx1, Panx2 and Panx3, of which 1 or more have been detected in every mammalian organ (Table 1) . Moreover, it has been reported that heteromeric channels consisting of Panx1 and Panx2 can be formed at the plasma membrane of X. laevis oocytes (Bruzzone, Barbe, Jakob, & Monyer, 2005) with an attenuated functional activity as observed by a decreased dye uptake and currents (Bruzzone, Hormuzdi, Barbe, Herb, & Monyer, 2003) . Posttranslational modifications, including phosphorylation, N-glycosylation and S-nitrosylation, are known to affect Panx trafficking and channel gating (Boyce, Epp, Nagarajan, & Swayne, 2017) . Panx channels can be activated in both physiological and pathological conditions. Although Panx1 channels open at positive potential, a number of triggers have been identified that promote their opening at membrane resting potential. These include the elevation of intracellular Ca 2+ concentration (Locovei, Bao, and Dahl, 2006; Locovei, Wang, and Dahl, 2006) , ATP binding to purinergic P 2 receptors, such as P 2 Y receptors (Locovei, Bao, and Dahl, 2006; Locovei, Wang, and Dahl, 2006) as well as ionotropic receptors, like P 2 X 7 receptors (Pelegrin & Surprenant, 2006) , oxygen deprivation (Weilinger, Tang, & Thompson, 2012) and mechanical stress (Locovei, Bao, and Dahl, 2006; Locovei, Wang, and Dahl, 2006) . The role of Panx channels in cell death (Chekeni et al., 2010; Cisneros-Mejorado et al., 2015; Sandilos et al., 2012; Xiao, Waldrop, Khimji, & Kilic, 2012) and inflammation (Brough, Pelegrin, & Rothwell, 2009; Crespo Yanguas et al., 2017; Csak et al., 2011; Ganz, Csak, Nath, & Szabo, 2011; Marina-García et al., 2008) has been well documented. In this review, an overview of chemical-based inhibitors of Cx and Panx channels is provided, including glycyrrhetinic acid, carbenoxolone, alcohols, fenamates and quinine, RNA-based inhibitors, antibodies and peptide-based blockers.
Chemical-based inhibitors

Glycyrrhetinic acid and derivatives
Historically, 18α-glycyrrhetinic acid (GA) and 18β-GA were among the first compounds found to inhibit GJs. These pentacyclic triterpenoid saponins are molecular constituents of Glycyrrhiza glabra, also named licorice, which is known to perform anti-inflammatory, anti-ulcerous, hepatoprotective and immunomodulatory effects (Amagaya et al., 1984; Capasso, Mascolo, Autore, & Duraccio, 1983; Nose, Ito, Kamimura, Shimizu, & Ogihara, 1994) . These properties are partly due to GA's mineralocorticoid and glucocorticoid receptor binding capacity as well as to 11β-hydroxysteroid dehydrogenase inhibition (Armanini, Karbowiak, & Funder, 1983 Table 2) . GA affects many different GJs without being Cx subtype specific (Bodendiek & Raman, 2010) , but detailed selectivity studies are lacking. The mode of inhibitory action of GA is still not completely understood. Direct interaction between GA and GJs is possible when the former is inserted into the plasma membrane, thereby binding to GJs and causing a conformational alteration (Davidson & Baumgarten, 1988; Davidson, Baumgarten, & Harley, 1986) . This mechanism has been suggested based on the observation of rapid onset and reversal of inhibition (Davidson et al., 1986 ), yet the reproducibility of this effect has been questioned (Spray, Rozental, & Srinivas, 2002) . Other possibilities include changes in the Cx phosphorylation status, which lead to a reduction in Cx expression (Goldberg et al., 1996; Guan, Wilson, Schlender, & Ruch, 1996) . When administered in vivo, GA exhibits protective effects in a mouse model of allergic asthma (Kim, Griffin, et al., 2017; Kim, Hong, et al., 2017) , kidney injury (Abd El-Twab, Hozayen, Hussein, & Mahmoud, 2016; Wu, Chen, & Yen, 2015) , auto-immune encephalomyelitis (Zhou et al., 2015) , CCl 4 -induced liver fibrosis (Chen, Gao, et al., 2013; Chen, Toth, et al., 2013; Chen, Zou, et al., 2013) , lipopolysaccharide-induced vascular permeability (Kim et al., 2013) , lipopolysaccharide-induced hepatic failure , gastritis and gastric tumorigenesis (Cao et al., 2016) , acetaminophen-induced liver toxicity (Yang, Jiang, Li, & Mao, 2015) and obese animal models (Park et al., 2014) , which is probably due to its anti-inflammatory action.
Carbenoxolone, a more water-soluble derivate of GA, has different cellular targets and also acts as an inhibitor of 11β-hydroxysteroid dehydrogenase (Armanini, Karbowiak, Krozowski, Funder, & Adam, 1982 (Amagaya et al., 1984; Armanini et al., 1982; Armanini et al., 1983; Böhmer et al., 2001; Bruzzone et al., 2005; Davidson & Baumgarten, 1988; Davidson et al., 1986; Eskandari et al., 2002; Locovei et al., 2007; Matchkov et al., 2004; Su et al., 2007; Walker & Edwards, 1991 (Bruzzone et al., 2005; Bühler, Perschel, & Hierholzer, 1991; Bujalska, Shimojo, Howie, & Stewart, 1997; Davidson & Baumgarten, 1988; Davidson et al., 1986; John et al., 1999; Ma et al., 2009; Pelegrin & Surprenant, 2006; Ripps et al., 2002 Ripps et al., , 2004 Suadicani, Brosnan, & Scemes, 2006 (Bernardini et al., 1984; Délèze & Hervé, 1983; Dildy-Mayfield, Eger, and Harris, 1996; Dildy-Mayfield, Mihic, et al., 1996; Guan et al., 1997; Johnston et al., 1980; Matchkov et al., 2004; Meda et al., 1986; Suadicani et al., 2006; Weingart & Bukauskas, 1998 (Bernardini et al., 1984; Délèze & Hervé, 1983; Dildy-Mayfield, Eger, and Harris, 1996; Dildy-Mayfield, Mihic, et al., 1996; Eskandari et al., 2002; Guan et al., 1997; Hirche, 1985; Johnston et al., 1980; Meda et al., 1986; Todorovic & Lingle, 1998; Weingart & Bukauskas, 1998) Halothane GJs in cardiac cells, neonatal rat cardiac myocytes (2 mM), crayfish axons (IC 50 28.5 mM), cultured astrocytes (0.1-1 mM), hippocampal slices (2.8 mM)
Inhibition of TTX-resistant and TTX-sensitive Na + channels, excitatory synaptic transmission, G-protein-activated K + channel currents, muscarinic receptors, NMDA receptors, thromboxane A2 signaling; glutamate receptors (Banks & Pearce, 1999; Beirne, Pearlstein, Massey, & Warner, 1998; Burt & Spray, 1989; Dildy-Mayfield, Eger, and Harris, 1996; Dildy-Mayfield, Mihic, et al., 1996; Hauswirth, 1969; Hönemann et al., 1998; Jones & Harrison, 1993; Krnjević, 1992; Mantz et al., 1993; Milovic, Steinecker-Frohnwieser, Schreibmayer, & Weigl, 2004; Minami et al., 1997; Peracchia, 1991; Scholz et al., 1998; Sirois et al., 1998; Wentlandt et al., 2006) 
Oleic acid
GJs in vascular smooth muscle cells (0.1-1 μM), rat liver epithelial cell line (20 μM) and cultured rat astrocytes (50 μM)
TRPV1 in HEK293 cells (5 μM), ATP-sensitive K + channels (100 μM), Cl − channels (6.5 μM) (Bai et al., 2013; Hii et al., 1995; Hirschi et al., 1993; Lavado et al., 1997; Linsdell, 2000; Morales-Lázaro et al., 2016) 
Linoleic acid
GJs in rat liver epithelial cell line (0.01-3 mg/dL), HCs: Cx46 activation (0.1 μM) and inhibition (100 μM) in X. laevis oocytes, inhibition of Cx26, Cx32, Cx43, Cx45 in HeLa cells (100 μM), Cx43 in human gastric epithelial cells Cl − channels in hamster kidney cell lines (6.5 μM), Na + currents in rat ventricular myocytes (IC 50 26 μM) (Figueroa et al., 2013; Hayashi et al., 1997; Kang & Leaf, 1996; Leifert, McMurchie, & Saint, 1999; Linsdell, 2000; Puebla et al., 2016; Retamal et al., 2011) Arachidonic acid GJs in cells derived from rat lacrimal glands (50-100 μM), neonatal rat heart cells (4 μM), Cx36-HeLa cells (10 μM), Panx1 channel inhibition in X. laevis oocytes (100 μM) Cl − channels in hamster kidney cell lines (6.5 μM),
-channel activity in rat arteriolar mycoytes (10 μM) (Bai, Ding, Kojima, Seto, & Matsuura, 2015; Fluri, Rüdisüli, Willi, Rohr, & Weingart, 1990; Giaume, Randriamampita, & Trautmann, 1989; Heler, Bell, & Boland, 2013; Kur et al., 2014; Linsdell, 2000; Safrany-Fark et al., 2015; Samuels, Lipitz, Wang, Dahl, & Muller, 2013; Schmilinsky-Fluri, Valiunas, Willi, & Weingart, 1997; Xiao et al., 2012) Palmitic acid Panx1 channel activation in human and rat liver cell lines (100-500 μM)
Cl − channels (6.5 μM) (Linsdell, 2000; Xiao et al., 2012) receptors (655 nM) (Coyne, Su, Patten, & Halliwell, 2007; de Roos, Willems, Peters, van Zoelen, & Theuvenet, 1997; Doughty, Miller, & Langton, 1998; Eskandari et al., 2002; Farrugia et al., 1993; Gögelein et al., 1990; Greenwood & Large, 1995; Grover et al., 1994; Harks et al., 2001; Lee & Wang, 1999; Li et al., 1998; McCarty et al., 1993; Ottolia & Toro, 1994; Srinivas & Spray, 2003; Suadicani et al., 2006; Wang, Dixon, and McKinnon, 1997; Wang, Wang, Yu, and Kotlikoff, 1997; White & Aylwin, 1990; Zhang, McBride, & Hamill, 1998; Zhou et al., 2002) release (IC 50 42 μM), P-glycoprotein (1-20 μM), (Coker et al., 2000; Cruikshank et al., 2004; Kang et al., 2001; Lee & Go, 1996; Pham et al., 2000; Srinivas et al., 2005; Yamamoto & Suzuki, 2008) (continued on next page) 34 μM) in X. laevis oocytes and GJs (Ripps, Qian, & Zakevicius, 2002 (Table 2) . Recently, the mechanism of Panx1 channel inhibition of carbenoxolone has been elucidated. It seems that a mutation in the first EL reverses its action polarity and potentiates the voltage-gated channel activity of the Panx1 channel (Michalski & Kawate, 2016) . Carbenoxolone displays different protective effects in a model of Parkinson's disease (Thakur & Nehru, 2015) , ischemic brain injury (Tamura, Alessandri, Heimann, & Kempski, 2011; Zhang et al., 2013) , posttraumatic epilepsy (Chen, Gao, et al., 2013; Chen, Toth, et al., 2013; Chen, Zou, et al., 2013) , allergic airway inflammation (Ram, Singh, Singh, Kumar, & Ghosh, 2009 ) and fatty liver disease in obese mice (Rhee et al., 2012) . As for steroid hormones, such as testosterone, 17β-estradiol, cortisone and their esters were found to impair GJIC independent of the shape of the molecules (25 μM), but correlated with their size and lipophilicity (Hervé et al., 1996) . Nevertheless, presence of the ester chain is necessary for inhibition of GJIC. This corresponds with the hypothesis that the mechanism of inhibition is an indirect effect of these structures. Indeed, the ester chains are incorporated in the lipid bilayer in the plasma membrane, thereby disturbing the organization of Cx channels (Goldberg et al., 1996) .
Long-chain alcohols
Heptanol and octanol are often used as fragrances in perfumes and cosmetics because of their pleasant smell. Heptanol triggers Ca 2+ -activated and ATP-sensitive K + channels, but inhibits voltage-gated Ca 2+ channels (Matchkov et al., 2004 ). On its turn, octanol blocks Na + currents and T-type of Ca 2+ channels (122 μM) and potentiates γ-amino butyric acid (GABA) responses in X. laevis oocytes (50 μM) (Dildy-Mayfield, Eger, and Dildy-Mayfield, Mihic, et al., 1996; Hirche, 1985; Todorovic & Lingle, 1998) . Both molecules inhibit P 2 X 7 receptors and enhance glycine receptor function. Heptanol and octanol have been reported to inhibit GJs in the crayfish giant axon, rat glial cells and insect cells (Guan et al., 1997; Johnston, Simon, & Ramón, 1980; Weingart & Bukauskas, 1998) . Furthermore, they have been shown to block GJIC in cardiac cells (Délèze & Hervé, 1983) , stomach and pancreatic epithelial cells (Bernardini, Peracchia, & Peracchia, 1984) or pancreatic acinar cells (Meda, Bruzzone, Knodel, & Orci, 1986) . Heptanol causes a stepwise decrease of ion current, mediated by Cx43 HCs, in a planar lipid bilayer (10 μM) (Brokamp, Todd, Montemagno, & Wendell, 2012) . Octanol also inhibits Cx50 currents (IC 50 177 μM) (Eskandari et al., 2002) (Table 2 ). The inhibitory actions of long-chain alcohols on GJs have been related to their deleterious effects on membrane fluidity (Bastiaanse, Jongsma, van der Laarse, & Takens- Kwak, 1993; Takens-Kwak, Jongsma, Rook, & Van Ginneken, 1992) . Heptanol reduces GJ conductance by decreasing fluidity, in particular of cholesterol-rich membrane domains, in which GJs are embedded (Bastiaanse et al., 1993) . The structural requirement for inhibition of GJs seems to be a certain length of the carbohydrate chain and therewith a given lipophilicity (Bodendiek & Raman, 2010) . Heptanol has a marked protective effect on cell death during reoxygenation injury (Rodriguez-Sinovas, Garcia-Dorado, Ruiz-Meana, & Soler-Soler, 2006) and ischemia (Chen, Mao, Fan, Bruce, & Xia, 2005; Miura et al., 2004) in rat heart.
Halothane and enflurane
Halothane and enflurane, both halogenated volatile anesthetics, have the ability to inhibit GJs in neonatal cardiac myocytes. Enflurane, isoflurane and halothane have been found to inhibit GJs in crayfish axons (Peracchia, 1991) , cultured astrocytes (Mantz, Cordier, & Giaume, 1993) and hippocampal slices (Wentlandt, Samoilova, Carlen, & El Beheiry, 2006) . They also affect several other cellular targets, such as tetrodotoxine (TTX)-resistant and TTX-sensitive Na + channels, excitatory synaptic transmission, G-protein-activated K + channel currents, muscarinic receptors via protein kinase C, antagonization of glutamatergic neurotransmission at N-methyl-D-aspartate (NMDA) receptors, thromboxane A2 signaling and a number of glutamate receptor subtypes (Banks & Pearce, 1999; Burt & Spray, 1989; Dildy-Mayfield, Eger, and Harris, 1996; Dildy-Mayfield, Mihic, et al., 1996; Hönemann, Nietgen, Podranski, Chan, & Durieux, 1998; Jones & Harrison, 1993; Mantz et al., 1993; Minami, Vanderah, Minami, & Harris, 1997; Scholz, Appel, & Vogel, 1998; Sirois, Pancrazio, Lynch, & Bayliss, 1998; Wentlandt et al., 2006) (Table 2) . Halothane seems to have a certain Cx subtype specificity since at μM concentrations, heteromeric Cx40/ 43 channels are more sensitive than homomeric Cx40 or Cx43 channels (Bodendiek & Raman, 2010) . The underlying mechanism is believed to be similar to that of long-chain alcohols (Bodendiek & Raman, 2010) . However, it has been suggested that direct interaction between lipophilic compounds and susceptible membrane proteins occurs, which is supported by experiments showing that halothane binds to hydrophobic cavities in proteins (Johansson, Scharf, Davies, Reddy, & Eckenhoff, 2000) . Halothane is known to induce liver injury (Soleimanpour, Safari, Rahmani, Ameli, & Alavian, 2015) , but when applied in vivo, halothane can perform protective effects in acetylcholine-induced bronchoconstriction (Lele, Petak, Fontao, Morel, & Habre, 2006) , retinal light damage (Keller, Grimm, Wenzel, Hafezi, & Reme, 2001 ) and myocardial reperfusion injury (Schlack, Preckel, Stunneck, & Thamer, 1998) .
Fatty acids
Fatty acids are classified based upon the length of their aliphatic carbon chain and the number of double bonds. Oleic acid, arachidonic acid and docosahexaenoic acid were the first fatty acids to show strong inhibitory effects on GJs in heart, vascular smooth muscle and liver Wang et al., 2013a Wang et al., , 2013b epithelial cell lines (Hii et al., 1995; Hirschi, Minnich, Moore, & Burt, 1993) . Later on, arachidonic acid, linoleic acid and lauric acid were found to perform similar actions on GJs in cells derived from rat lacrimal glands. It is, however, still not clear whether these effects are caused by direct interaction of fatty acids with the Cx structure or if an indirect effect via protein kinases is involved (Upham et al., 2009 ). Linoleic acid was also shown to increase Cx HC activity in HeLa cells transfected with Cx26, Cx32, Cx43 or Cx45 within a few minutes of exposure (Figueroa et al., 2013) . Furthermore, linoleic acid increases Cx43 HC activity in a human gastric epithelial cell line (Puebla et al., 2016) . Linoleic acid has a biphasic effect on Cx46, by increasing HC currents at low concentrations (0.1 μM) and decreasing at high concentrations (100 μM) without affecting GJs (Retamal, Evangelista-Martínez, León-Paravic, Altenberg, & Reuss, 2011) . Panx1 channel activity is increased in human and rat liver cell lines upon treatment with palmitic acid and stearic acid (Xiao et al., 2012) , but this effect probably depends on the degree of saturation (Puebla et al., 2017) (Table 2 ). Certain fatty acids could have a beneficial outcome in diabetic nephropathy (Hills, Price, & Squires, 2015) , lens cataract , hypertension (Fischer et al., 2008) and cancer (Aasen, Mesnil, Naus, Lampe, & Laird, 2016) .
Fenamates
Fenamates belong to the class of N-phenylanthranilic acids and are widely used as nonsteroidal anti-inflammatory drugs because of their ability to inhibit cyclo oxygenases (Brogden, 1986) . In addition, fenamates modulate a diversity of ion channels. They have been identified as inhibitors of voltage-gated and ATP-sensitive K + channels (Grover et al., 1994; Lee & Wang, 1999) (White & Aylwin, 1990 ) and non-selective cation channels (Gögelein et al., 1990) . On the other hand, fenamates have been shown to activate Ca 2+ -activated and voltage-dependent K + channels (Farrugia, Rae, & Szurszewski, 1993; Ottolia & Toro, 1994) . They were also found to block P 2 X 7 receptors (IC 50 655 nM). Flufenamic acid inhibits GJs composed of Cx26, Cx32, Cx40, Cx43, Cx46, and Cx50 in N2A mouse neuroblastoma cells (100 μM) and HCs consisting of Cx50, Cx46 and Cx38 in X. laevis oocytes (Table 2) . They seem to function as chemical modifiers of channel gating, presumably by binding directly to a putative binding site within the membrane not accessible from the intracellular side (Bodendiek & Raman, 2010) . Flufenamate provides protection against ischemic insult in isolated retina of chick embryos (Chen, Olney, Lukasiewicz, Almli, & Romano, 1998 ).
Quinine and analogs
Found in the bark of the cinchona tree, quinine has antipyretic, antiinflammatory and analgesic properties, but is also widely used for its bitter taste in tonic water. Today, it is still used as a back-up drug for the treatment of infections related to the resistant plasmodium falciparum. It is also used for treating benign nocturnal leg cramps (Young, 2002) . Quinine affects many different cellular targets, including ion channels, receptors, transporters and enzymes. It blocks ATP-sensitive (IC 50 3 μM) and voltage-gated K + channels (IC 50 8 μM) (Lin, Chen, & Tee, 1998; Wang, Inukai, Greer, & Greer, 1994) , inhibits Na + currents (85 μM) (Lin et al., 1998) Table 2) .
A stereo-isomer of quinine, called quinidine, has also been found in the bark of the cinchona tree. It is used in the treatment of arrhythmias (Grace & Camm, 1998 (Beckman, Pramod, Perley, & Henry, 2014) . The quaternary quinine derivate N-benzylquininium inhibits Cx50 HCs and has been suggested to bind to its N-terminal tail (Rubinos, Sánchez, Verselis, & Srinivas, 2012) (Table 2 ). Quinidine protects the gut from platelet activating factor-induced vasoconstriction, edema and paralysis (Lautenschlager et al., 2015) and hypothermia-induced ventricular tachycardia and fibrillation (Gurabi, Koncz, Patocskai, Nesterenko, & Antzelevitch, 2014 (Yamamoto & Suzuki, 2008) . Moreover, mefloquine inhibits Cx26 (IC 50 16 μM) and Cx50 HC currents when expressed in X. laevis oocytes (Levit et al., 2015) (Table 2) . Interestingly, mefloquine suppresses tremor in a mouse model of essential tremor and inhibits cortical spreading depression in a rat neocortical slice model (Margineanu & Klitgaard, 2006; Martin & Handforth, 2006) .
2-Aminoethoxydiphenyl borate
2-Aminoethoxydiphenyl borate (2-APB), an IP 3 receptor modulator, inhibits capacitive current transients, reflecting GJ blockage, in normal rat kidney and HEK293 cells. 2-APB was also found to affect store-operated Ca 2+ channels. In N2A neuroblastoma cells, 2-APB inhibits conductance of GJs composed of Cx36, Cx40 and Cx50 (IC 50 3 μM) as well as Cx26, Cx30 and Cx45 (IC 50 18 μM) (Bai, del Corsso, Srinivas, & Spray, 2006) . It also inhibits transient receptor potential (TRP) channels TRPC1, TRPC3, TRPC5, TRPC6, TRPC7, TRPM3, TRPM7, TRPM8 and TRPP2, yet its inhibition seems to be often incomplete (Bai et al., 2006; Chung, Lee, Mizuno, Suzuki, & Caterina, 2004; Colton & Zhu, 2007; Harks et al., 2003; Hu et al., 2004; Ma et al., 2001; Maruyama, Kanaji, Nakade, Kanno, & Mikoshiba, 1997) . Its boro-axozolidine ring seems to be an essential part of the pharmacophore for blocking Ca 2+ release (Table 2) . Since diphenhydramine and phenytoin, both lacking the boroaxozolidine ring, block GJs, it has been suggested that the pharmacophore for the inhibition of GJs differs from the one responsible for suppressing Ca 2+ release. Regarding the pharmacophore for GJ inhibition, it seems that a diphenyl moiety, linked by boron, a tetrahedral carbon or an oxygen is required and allows effective interaction with the channel or access to the channel by decent lipid solubility (Tao & Harris, 2007) . 2-APB protects against acetaminophen hepatotoxicity when co-administered with acetaminophen. However follow-up study demonstrated the protection was only minor or completely lost when administered at later time points. In addition part of the effect could be attributed to solvent effect as well as by inhibiting cytochrome P450 enzymes and c-jun N-terminal kinase activation (Du et al., 2013) .
Polyamines and cyclodextrins
Polyamines, like spermine and spermidine, are endogenous molecules present in nearly every cell and involved in processes, such as protein synthesis, cell division and growth (Pegg, 2009) . Polyamines also modulate a number of ion channels, including Kir and NMDA channels (Williams, 1997) . Spermine was found to inhibit Cx40 GJs in a transjunctional voltage-dependent manner (IC 50 100 μM) (Musa, Gough, Lees, & Veenstra, 2001; Musa et al., 2004) (Table 2) . Spermine protects against lipopolysaccharide-induced memory deficits (Fruhauf et al., 2015) and pentylenetetrazol-induced kindling epilepsy in mice (Kumar & Kumar, 2017) , and attenuates behavioral and biochemical alterations induced by quinolinic acid in the striatum of rats (Velloso et al., 2008) .
The cyclodextrin ring structure with a hydrophobic inner cavity and a hydrophilic outer surface allows to capture lipophilic compounds in the cavity and to enhance their water solubility. Cyclodextrins enter into the Cx pore lumen via the cytoplasmic side followed by direct occlusion of the pore. Spermidine protects against oxidative stress in inflammation models using macrophages (Jeong et al., 2017) , is neuroprotective (Buttner et al., 2014; Wang, Tsai, & Shen, 2015; Yang et al., 2017) , reduces blood pressure and decreases risk of cardiovascular disease (Eisenberg et al., 2017) and alleviates laurate-induced brain injury .
Probenecid and Brilliant Blue FCF
Probenecid is a widely used drug for the treatment of gout and is a well-known blocker of organic anion transporters. Probenecid is used clinically to increase effective concentrations of antibiotics, chemotherapeutics and other drugs. It has been shown that probenecid inhibits Panx1 channel currents in a concentration-response manner (IC 50 150 μM) (Silverman, Locovei, & Dahl, 2008) in oocytes, but not HCs consisting of Cx46 and Cx32. The proposed mechanism of action is similar to CBX, namely by interactions with the first extracellular loop of Panx1 (Amacher, 2011) .
Probenecid also blocks P 2 X 7 -mediated dye uptake (IC 50 203 μM) in HEK-P 2 X 7 cells and human monocytes (Bhaskaracharya et al., 2014) (Table 2 ). Probenecid prevents acute tubular necrosis in mice (Baudoux et al., 2012) , cerebral ischemia/reperfusion injury in rats (Wei et al., 2015) and oxygen/glucose deprivation injury in neocortical mouse astrocytes (Jian et al., 2016) .
The food dye FD&C Blue no. 1 or Brilliant Blue FCF is structurally similar to Brilliant Blue, which is a well-known inhibitor of the ionotropic P 2 X 7 receptor. It has been reported that Brilliant Blue FCF selectively inhibits Panx1 channels (IC 50 0.27 μM) as evidenced by blockage of voltage-activated currents and inhibition of ATP release in X. laevis oocytes (Wang et al., 2013c) . It seems that the binding of Brilliant Blue FCF to Panx1 is similar to ATP, in the sense that positively charged amino acids are involved in forming the binding site (Wang et al., 2013c) (Table 2) . Brilliant Blue FCF acts in a neuroprotective way (Wang, Xie, Luo, Shang, & He, 2017) , has protective effects on graft versus host disease and improves liver function (Zhong et al., 2016) .
RNA-based inhibitors
Following the discovery of RNA interference (RNAi) (Fire et al., 1998) , it became clear that 20-30 nucleotide-long RNAs control the expression of genetic information (Carthew & Sontheimer, 2009 ). Dicer, a ribonuclease protein, cleaves double-stranded RNA (dsRNA) into dsRNA duplexes of a specific length, known as short interfering RNA (siRNA), consisting of 21-23 nucleotides. Each siRNA associates with the RNA-induced silencing complex (RISC). Subsequently, the endonuclease Argonaute component of the RISC cleaves the passenger strand of siRNA, while the guide strand can target a specific mRNA through base-pairing to influence its activity (Lam, Chow, Zhang, & Leung, 2015) . Although microRNAs (miRNAs) and siRNAs are similarly associated with Dicer and RISC, they both have different effects. Specifically, miRNAs inhibit the expression of multiple mRNAs, while siRNAs regulate the expression of 1 specific target mRNA (Deng et al., 2014) . Short hairpin RNAs (shRNAs) can also be used to influence the RNAi mechanism. shRNAs are stem-loop RNAs expressed in the nucleus usually via viral vectors. They are transported to the cytoplasm to load into RISC for specific gene targeting similar to siRNAs (Rao, Vorhies, Senzer, & Nemunaitis, 2009) . In this way, RNAi controls vital processes, such as cell growth, tissue differentiation and heterochromatin formation (Lu et al., 2008) . RNAi is widely used for its application in experimental biology to study the function of specific genes, but is equally important as a potential therapeutic strategy for the treatment of a number of highly prevalent diseases, such as cancer, neurodegenerative disorders, cardiovascular diseases and viral infections (Crowe, 2003; Izquierdo, 2005; Jia, Zhang, & Liu, 2006; Kusov, Kanda, Palmenberg, Sgro, & Gauss-Müller, 2006) .
RNAi can be applied to target specific Cx and Panx species. In this respect, Cx43 expression and thus channel functionality, have been successfully suppressed (around 70%) using RNAi-based approaches in human bone marrow stromal cells (Talbot et al., 2017) , human bronchial fibroblasts (Paw et al., 2017) , rat renal tubular epithelial cells (Chi et al., 2016) , human ovarian cancer cell lines (Qiu et al., 2016) , human pulmonary endothelial cells (O'Donnell, Birukova, Beyer, & Birukov, 2014) , mouse 3T3 fibroblasts and HL-1 cardiomyocytes (Osbourne et al., 2014) , and murine bone marrow-derived dendritic cells (Yu, Yan, Nie, & Zhu, 2016) , Likewise, in a number of preclinical models of tissue damage and wound repair, reducing protein translation of Cx43 mRNA using antisense oligodeoxynucleotides (5-GTAATTGCGGCAGGAGG AATTGTTTCTGTC-3) has been demonstrated to decrease inflammation, edema and lesion spread, and to provide improved healing or functional outcomes. This has been observed in skin incision and excision wounds (Mori, Power, Wang, Martin, & Becker, 2006; C. Qiu et al., 2003) , skin burns (Coutinho et al., 2005) and the cornea of the eye (Grupcheva et al., 2012) . In human patients with severe chemical or thermal burns, Cx43 antisense oligodeoxynucleotides reduce inflammation within 1 to 2 days, and induce complete and stable corneal re-epithelialization (Ormonde et al., 2012) .
Antibody-based inhibitors
Cx antibodies that are used as inhibitors usually target the extracellular sites of desired Cx subtypes. However, the mechanism that links targeting extracellular Cx epitopes with inhibition of Cx channels remains unknown (Riquelme, Kar, Gu, & Jiang, 2013) . The injection of fragments of antibodies, named Gap13 and Gap15, raised against the CL regions of Cx43, allowed to interrupt GJIC in mouse embryos (Becker, Evans, Green, & Warner, 1995) . Similar results have been obtained with fragments targeting the CL of Cx32 in rabbit tracheal airway epithelial cells (Boitano, Dirksen, & Evans, 1998) . Furthermore, re-aggregated Novikoff cells treated with antibodies directed against the second EL domains of Cx43 showed markedly reduced cell-cell dye transfer. Neither GJs nor formation plaques were observed between cells, indicating that the antibodies prevented the assembly of GJ structures in contrast to simple closure of GJs (Meyer, Laird, Revel, & Johnson, 1992) (Table 3) . Antibodies directed against the extracellular domains of Cx proteins offer an interesting approach, because the ELs of unopposed Cx HCs are accessible, while this is not the case in GJs, where the loops are engaged in docking interactions. As a consequence, they are expected to specifically affect free Cx HCs, but not GJs. A possible drawback relates to the fact that the ELs are well-conserved between different Cxs, enabling the antibodies to affect HCs composed of other Cx isotypes (Hervé & Dhein, 2010) .
Peptide-based inhibitors
Peptides targeting the connexin extracellular loop
Given its ubiquitous presence in a wide spectrum of cells, most efforts to produce Cx mimetic peptide have been focused on Cx43 (Table 1) (Willecke et al., 2002) . Among the first peptides were 43 Gap26 and 43 Gap27, which reproduce the amino acid sequences VCYD and SRPTEK, respectively, in the first and second EL of Cx43 (Fig. 2) . These peptides are thought to interact with complementary sites within the EL regions of Cx43 of opposing HCs, and thereby to prevent their docking and hence the formation of GJs . In course of time, it has been found that they also affect Cx32, Cx40 and Cx37 channels (De Vuyst et al., 2006; . In vitro, both 43 Gap26 (0.25 mg/L) and 43 Gap27 (3-300 μM) inhibit Cx HC-mediated ATP release and dye uptake upon short exposure (Braet et al., 2003; Eltzschig et al., 2006) , while longer exposures also result in the suppression of the corresponding GJ activity (Braet et al., 2003; Decrock et al., 2009 Gap27 may have effects on Cx43 phosphorylation, especially occurring at serine368, and therefore could influence Cx43 channel activity (Solan & Lampe, 2005 ). Both peptides have been used extensively in studies of the immune system (Matsue et al., 2006; Neijssen, Pang, & Neefjes, 2007; Neijssen et al., 2005; Oviedo-Orta, Gasque, & Evans, 2001) , vascular system (Chaytor, Evans, & Griffith, 1997; Matchkov et al., 2006) , heart (Davidson et al., 2012; Hawat, Benderdour, Rousseau, & Baroudi, 2010) , lung (Sarieddine et al., 2009 ), brain (De Bock et al., 2012 , skin (Evans & Leybaert, 2007; Pollok et al., 2011; Wright et al., 2009 ) and liver (Vinken, Decrock, Vanhaecke, Leybaert, & Rogiers, 2012) . In order to generate more specific inhibitors, a modified Gap27 peptide, namely 40 Gap27, was developed. This peptide incorporates a sequence in the second EL of Cx40 and has also proven useful in vascular tissues (Sorensen, Salomonsson, Braunstein, Nielsen, & Holstein-Rathlou, 2008) . The same was performed for a part of the second EL of Cx32, generating 32 Gap27 (Fig. 2) , which showed inhibition of ATP release in primary hepatocytes (0.25 mg/mL) and no effect on GJ activity (Vinken et al., 2010) .
43
Gap26M is a modified version of
Gap26 that has an acylated Nterminus and shows greater solubility and stability.
Gap26M significantly increased migration rates across scrapes in keratinocytes and fibroblasts by blocking GJ functionality (Wright et al., 2009) .
Peptide5 (VDCFLSRPTEKT) is a peptide shifted 5 amino acids in Nterminal direction compared to Gap27 (Fig. 2) (Danesh-Meyer et al., 2012) . It inhibits Cx HCs at low (5-10 μM) concentration, while equally inhibiting GJs at higher concentration (100 μM) (O'Carroll, Alkadhi, Nicholson, & Green, 2008) . In vitro, peptide5 has been used to study a variety of cellular processes, such as dynamic Ca 2+ signals (Braet et al., 2003) , release of neurotransmitters (Romanov et al., 2007) as well as propagation of cell death . In vivo, peptide5 reduces tissue damage secondary to spinal cord injury and attenuates a vascular permeability increase following retinal ischemia/reperfusion insult Chen, Gao, et al., 2013; Chen, Toth, et al., 2013; Chen, Zou, et al., 2013; Guo et al., 2016; Kim, Griffin, et al., 2017; Kim, Hong, et al., 2017; O'Carroll, Gorrie, Velamoor, Green, & Nicholson, 2013) (Table 4) .
Peptides targeting the connexin cytoplasmic loop
The L2 peptide, corresponding to a sequence in the CL moiety of Cx43, inhibits its HC opening without affecting GJs independent of the time of exposure (Seki, Coombs, Taffet, & Delmar, 2004) . Based on this observation, the hypothesis was raised that prevention of the interaction between the CT and the CL areas of Cx43 leads Cx HC closure, which means that this interaction is necessary for Cx HC opening. By contrast, CT-CL interaction results in the closure of GJs. Indeed, physical binding of the CT and the L2 region of Cx43 in the CL induces a residual state with very low conductance (Ponsaerts et al., 2010) .
It has been shown that Gap19, a synthetic nonapeptide (KQIEIKKFK) derived from the CL region of Cx43, inhibits its HC activity without influencing the corresponding GJ activity over time. Cx HC inhibition is due to the binding of Gap19 to the CT area of Cx43, thereby preventing intramolecular CT-CL interactions (Wang et al., 2013a (Wang et al., , 2013b . By doing so, Gap19 was found to inhibit Cx43 HCs in Cx43-overexpressing C6 rat glioma cells (Wang et al., 2013a (Wang et al., , 2013b , cultured primary mouse astrocytes and murine hippocampal slices (Abudara et al., 2014) . Treatment with Gap19 protects cardiomyocytes against volume overload and cell death following ischemia/reperfusion in vitro and modestly decreases the infarct size after myocardial ischemia/reperfusion in mice (Wang et al., 2013a (Wang et al., , 2013b -triggered ATP responses in ECV304 bladder cancer epithelial cells (De Vuyst et al., 2006) . However, it was found that 32 Gap24 also attenuated Panx currents in a dose-dependent manner (500 μM-2 mM) (Wang, Lincoln, et al., 2007; Wang, Ma, et al., 2007) . It is believed that 32 Gap24 acts in a mechanistically similar way as Gap19 (Table 4) .
Peptides targeting the pannexin extracellular loop
10 Panx1, a synthetic peptide that mimics a sequence (WRQ AAFVDSY) in the second EL area of Panx1 (Fig. 2) , was introduced as a tool to elucidate the role of Panx1 in the caspase 1 cascade that leads to the induction of inflammatory responses (Brough et al., 2009; Chekeni et al., 2010) . This peptide, which potently inhibits Panx1 currents, dye uptake and ATP release in primary astrocyte cultures (200 μM), was found to counteract purinergic receptor activation and hence the maturation and ATP-mediated release of interleukin-1β in mouse and human macrophages. However,
10
Panx1 also inhibits Cx46 HCs in X. laevis oocytes (200 μM).
Panx1 has been successfully used in several other studies that substantiate the importance of Panx1 in the inflammasome in various cell types (Karpuk, Burkovetskaya, Fritz, Angle, & Kielian, 2011; Lamkanfi, Malireddi, & Kanneganti, 2009) , whereby it was shown that 10 Panx1 suppresses the production of interleukin-1α, interleukin-1β and interleukin-18 (Pelegrin, 2008) . Besides acting in an anti-inflammatory way,
Panx1 also protects against cell death in a number of cell types (Orellana et al., 2011; Pelegrin, 2008) and acetaminophen-induced hepatotoxicity in vivo . Furthermore, 10 Panx1 has been successfully used to inhibit ATP-induced ethidium bromide uptake coupled to P 2 X 7 receptors activation in (Murali, Zhang, & Nurse, 2017) (Table 4 ).
Conclusions
Gap junctions and Cx HCs play important roles in physiological and pathological processes in various organs, including brain, heart, blood vessels, liver, intestines, skin, lung and eye (Glass, Snyder, & Taffet, 2015; Kwak, Mulhaupt, Veillard, Gros, & Mach, 2002; Maes et al., 2015; Martin, Easton, Hodgins, & Wright, 2014; Meens, Kwak, & Duffy, 2015; Sarieddine et al., 2009; Scheckenbach, Crespin, Kwak, & Chanson, 2011; Willebrords et al., 2016) . The same holds true for Panx channels (Barbe, Monyer, & Bruzzone, 2006; Chen et al., 2010; Crespo Yanguas et al., 2017; Eugenin, 2014; Glass et al., 2015; Kurtenbach & Zoidl, 2014; Maes et al., 2015; Penuela, Harland, Simek, & Laird, 2014) . Several agents are currently available to inhibit Cx and Panx channels both as experimental tools or potential clinical therapeutics. Regarding the latter, Cx43 antisense oligodeoxynucleotides have yet been successfully used in clinical trials to treat severe ocular surface burns, with reduction of inflammation within 1 to 2 days and complete and stable corneal re-epithelialization when delivered in a gel structure (Ormonde et al., 2012 Panx1 (Pelegrin & Surprenant, 2007) . However, not all of these peptides specifically act on Cx HCs or Panx channels, and/or uniquely affect 1 Cx or Panx species (Bodendiek & Raman, 2010) . Although a multitude of protective effects have been observed by inhibition of GJs and HCs, a number of studies also demonstrates the promotion of cell death, as is the case for GA (Ozog, Siushansian, & Naus, 2002) , carbenoxolone (Tamura et al., 2011) and Cx43-targeted siRNA (Kar, Riquelme, Werner, & Jiang, 2013) .
While a plethora of information has been gathered regarding Cx and Panx channel inhibitors, less is known about activators of Cx and Panx channels. Retinoids and carotenoids have been found to exhibit chemopreventive effects through enhancement of GJIC and upregulation of Cx43 expression (Vine & Bertram, 2002) . Other GJ enhancers are polyphenols and flavonoids (Chaumontet et al., 1994; Stoner & Mukhtar, 1995) . Interestingly, several peptides that open these channels already entered clinical trials. Thus, ACT1 is a 25-amino acid synthetic peptide containing the CT of Cx43. Application of ACT1 in in vivo wound healing and ischemic cardiac injury studies revealed anti-inflammatory, anti-fibrotic and tissue regenerative properties through GJIC stabilization (Ghatnekar, Grek, Armstrong, Desai, & Gourdie, 2015; Gourdie et al., 2006; O'Quinn, Palatinus, Harris, Hewett, & Gourdie, 2011; Rhett et al., (Berman, Martin, Evans, & Griffith, 2002; Boitano & Evans, 2000; Braet et al., 2003; Clarke & Jump, 1996; D'hondt, Ponsaerts, et al., 2007; Gomes, Srinivas, Van Driessche, Vereecke, & Himpens, 2005; Pearson, Dale, Llaudet, & Mobbs, 2005; Retamal et al., 2007; Romanov et al., 2007; Shintani-Ishida, Uemura, & Yoshida, 2007; Vandamme, Braet, Cabooter, & Leybaert, 2004; Wang et al., 2008) (Berman et al., 2002; Boitano et al., 1998; Boitano & Evans, 2000; Braet et al., 2003; Chaytor et al., 1999; De Vuyst et al., 2006; Dora et al., 1999; Eltzschig et al., 2006; Gomes, Srinivas, Vereecke, & Himpens, 2006; Isakson, Evans, & Boitano, 2001; Kandyba, Hodgins, & Martin, 2008; Ko, Arora, Lee, & McCulloch, 2000; Oviedo-Orta, Errington, & Evans, 2002; Oviedo-Orta et al., 2000; Retamal et al., 2007; Samoilova, Wentlandt, Adamchik, Velumian, & Carlen, 2008; Wang et al., 2008; Warner, Clements, Parikh, Evans, & DeHaan, 1995; Wright et al., 2009) 40 Gap27 SRPTEKNVFIV EL2 Cx40 GJs Rat aorta endothelial cells (Sorensen et al., 2008) 32 Gap27 SRPTEKTVFT EL2 Cx32 HCs ECV304, Cx32-C6 cells, HEK293 cells, mouse microglia neurons, J774 murine macrophages, mouse taste cells (De Vuyst et al., 2006; Pelegrin & Surprenant, 2007; Takeuchi et al., 2006; Wright et al., 2009) Peptide5 VDCFLSRPTEKT EL2 Cx43 HCs GJs
Ex vivo rat spinal cord culture, human cerebral microvascular endothelial cells (Kim, Griffin, et al., 2017; Kim, Hong, et al., 2017; O'Carroll et al., 2013; Qiu et al., 2003) 43 Gap19 KQIEIKKFK CL Cx43 HCs Cx43-HeLa cells (Wang et al., 2013a (Wang et al., , 2013b 2008). Topical administration of this peptide augments healing of chronic neuropathic foot ulcers and venous leg ulcers in diabetic patients. Other GJ activators currently in clinical trials include rotigaptide and its dipeptide analogue GAP-134 as a drug for treating atrial fibrillation and endothelial dysfunction (Butera et al., 2009; Lang et al., 2008) . In general, peptides have evolved as highly potent signal transduction molecules, exerting powerful physiological effects. However, they are mostly characterized by a relatively short circulating plasma half-life as well as suboptimal physical and chemical properties, which are required for their use as therapeutics (Fosgerau & Hoffmann, 2015) . For this reason, it remains to be investigated whether Cx and Panx mimetic peptides as such can be used in clinical settings. Given the considerable therapeutic potential and translational relevance, future efforts should be focused in parallel on the generation of stable, potent and highly specific non-peptide modifiers of Cx and Panx channels.
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